title: Treatment options for hepatobiliary and pancreatic cancer.
abstract: Hepatobiliary and pancreatic cancers account for 4% of all cancers in the United States. Traditionally, these cancers have had a high mortality rate and have been poorly responsive to therapy. Because of a growing number of treatment options, patients are now living longer. For hepatocellular carcinoma, a broad number of treatment options are available, including surgery, ablation, embolization, systemic therapy, and liver transplantation. Treatment options for cholangiocarcinoma include surgery, systemic therapy, and liver transplantation. For pancreatic cancer, surgery, radiation, and systemic therapy all have potential roles. This review provides an updated summary of diagnosis and assessment together with treatment options for this group of cancers.
authors.affiliation: Division of Medical Oncology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA. alberts.steven@mayo.edu
authors.forename: Steven R
authors.initials: SR
authors.lastname: Alberts
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Gores
authors.forename: George P
authors.initials: GP
authors.lastname: Kim
authors.forename: Lewis R
authors.initials: LR
authors.lastname: Roberts
authors.forename: Michael L
authors.initials: ML
authors.lastname: Kendrick
authors.forename: Charles B
authors.initials: CB
authors.lastname: Rosen
authors.forename: Suresh T
authors.initials: ST
authors.lastname: Chari
authors.forename: James A
authors.initials: JA
authors.lastname: Martenson
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic; D006528:Carcinoma, Hepatocellular / Q000601:surgery; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000601:surgery*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000431:Ethanol / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery*; D016031:Liver Transplantation; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000431:Ethanol; D000093542:Gemcitabine